{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:16:35Z","timestamp":1788531395368,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,7,4]],"date-time":"2027-07-04T00:00:00Z","timestamp":1814659200000},"content-version":"am","delay-in-days":306,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P01DA009158"],"award-info":[{"award-number":["P01DA009158"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["T32DA055553"],"award-info":[{"award-number":["T32DA055553"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.drugalcdep.2026.113243","type":"journal-article","created":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T14:36:59Z","timestamp":1782052619000},"page":"113243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cannabinoid (CB) 1 receptor antagonists block fentanyl conditioned place preference but not fentanyl antinociception"],"prefix":"10.1016","volume":"286","author":[{"given":"Devin","family":"Morrisson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalal","family":"Alkhelb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanh","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lipin","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna W.","family":"Sromek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Makriyannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4053-5996","authenticated-orcid":false,"given":"Rajeev I.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.drugalcdep.2026.113243_bib1","article-title":"Effects of the cannabinoid CB1-receptor neutral antagonist AM4113 and antagonist\/inverse agonist rimonabant on fentanyl discrimination in male rats","volume":"240","author":"AlKhelb","year":"2022","journal-title":"Drug. Alcohol. Depend."},{"issue":"2","key":"10.1016\/j.drugalcdep.2026.113243_bib2","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s41386-025-02245-6","article-title":"Cannabinoid CB1 receptor and mu-opioid receptor interaction: new insights from conditional knockout mice","volume":"51","author":"Alton","year":"2026","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drugalcdep.2026.113243_bib3","article-title":"Interactions of the opioid and cannabinoid systems in reward: insights from knockout studies","volume":"6","author":"Befort","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2026.113243_bib4","series-title":"Understanding the Opioid Overdose Epidemic","author":"Centers for Disease Control and Prevention","year":"2024"},{"issue":"9600","key":"10.1016\/j.drugalcdep.2026.113243_bib5","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","article-title":"Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials","volume":"370","author":"Christensen","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.drugalcdep.2026.113243_bib6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/sj.bjp.0706756","article-title":"Opioid and cannabinoid receptors: friends with benefits or just close friends?","volume":"148","author":"Christie","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2026.113243_bib7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s00213-003-1422-1","article-title":"Cannabinoid CB1 receptors control conditioned drug seeking","volume":"168","author":"De Vries","year":"2003","journal-title":"Psychopharmacology"},{"issue":"20","key":"10.1016\/j.drugalcdep.2026.113243_bib8","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa044537","article-title":"Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia","volume":"353","author":"Despres","year":"2005","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2026.113243_bib9","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00213-025-06939-z","article-title":"Effects of the neutral CB1 receptor antagonist AM6527 on spontaneous, consummatory, and motivated behavior in mice","volume":"243","author":"Ecevitoglu","year":"2025","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drugalcdep.2026.113243_bib10","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s00213-005-0199-9","article-title":"Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviour in rats","volume":"183","author":"Economidou","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drugalcdep.2026.113243_bib11","first-page":"806","article-title":"Involvement of cannabinoid CB1 receptors in drug addiction: effects of rimonabant on behavioral responses induced by cocaine","volume":"58","author":"Filip","year":"2006","journal-title":"Pharmacol. Rep."},{"issue":"12","key":"10.1016\/j.drugalcdep.2026.113243_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyw068","article-title":"The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability","volume":"19","author":"Gueye","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.drugalcdep.2026.113243_bib13","article-title":"CB1 Receptor Activation on VgluT2-Expressing Glutamatergic Neurons Underlies \u03949-Tetrahhydrocannabinol (\u03949-THC)-Induced Aversive Effects in Mice","volume":"7","author":"Han","year":"2017","journal-title":"Sci. Rep."},{"issue":"20","key":"10.1016\/j.drugalcdep.2026.113243_bib14","doi-asserted-by":"crossref","first-page":"7693","DOI":"10.3390\/ijms21207693","article-title":"Cannabinoid Receptors: An Update on Cell Signaling, Pathophysiological Roles and Therapeutic Opportunities in Neurological, Cardiovascular, and Inflammatory Diseases","volume":"21","author":"Haspula","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.drugalcdep.2026.113243_bib15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41401-018-0059-x","article-title":"Cannabinoid CB1 receptor neutral antagonist AM4113 inhibits heroin self-administration without depressive side effects in rats","volume":"40","author":"He","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"issue":"3","key":"10.1016\/j.drugalcdep.2026.113243_bib16","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0306-4522(01)00509-7","article-title":"Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain","volume":"109","author":"Hermann","year":"2002","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.drugalcdep.2026.113243_bib17","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/bph.14860","article-title":"Fentanyl depression of respiration: Comparison with heroin and morphine","volume":"177","author":"Hill","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.drugalcdep.2026.113243_bib18","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1254\/jphs.08244FP","article-title":"Mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: Electrophysiological and FRET assay analysis","volume":"108","author":"Hojo","year":"2008","journal-title":"J. Pharmacol. Sci."},{"issue":"7","key":"10.1016\/j.drugalcdep.2026.113243_bib19","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/bph.15573","article-title":"The anomalous pharmacology of fentanyl","volume":"180","author":"Kelly","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2026.113243_bib20","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.physbeh.2015.06.005","article-title":"Intra-accumbal CB1 receptor blockade reduced extinction and reinstatement of morphine","volume":"149","author":"Khaleghzadeh-Ahangar","year":"2015","journal-title":"Physiol. Behav."},{"issue":"8","key":"10.1016\/j.drugalcdep.2026.113243_bib21","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1038\/sj.bjp.0703990","article-title":"Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction","volume":"132","author":"Mas-Nieto","year":"2001","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.drugalcdep.2026.113243_bib22","first-page":"1465","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2014","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drugalcdep.2026.113243_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fpain.2021.721357","article-title":"Opioids and Chronic Pain: An Analytic Review of the Clinical Evidence","volume":"2","author":"Nadeau","year":"2021","journal-title":"Front. Pain. Res."},{"key":"10.1016\/j.drugalcdep.2026.113243_bib24","series-title":"Guide for the Care and Use of Laboratory Animals: Eighth Edition","author":"National Research Council","year":"2011"},{"issue":"14","key":"10.1016\/j.drugalcdep.2026.113243_bib25","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1523\/JNEUROSCI.21-14-05344.2001","article-title":"Functional Interaction between Opioid and Cannabinoid Receptors in Drug Self-Administration","volume":"21","author":"Navarro","year":"2001","journal-title":"J. Neurosci."},{"issue":"9","key":"10.1016\/j.drugalcdep.2026.113243_bib26","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/npp.2017.51","article-title":"Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis","volume":"42","author":"Nielsen","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.drugalcdep.2026.113243_bib27","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/BF02244991","article-title":"Sensitization and tolerance to the discriminative stimulus effects of mu-opioid agonists","volume":"114","author":"Paronis","year":"1994","journal-title":"Psychopharmacology"},{"issue":"10","key":"10.1016\/j.drugalcdep.2026.113243_bib28","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrn4004","article-title":"Endocannabinoid signaling in reward and addiction","volume":"16","author":"Parsons","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"issue":"2","key":"10.1016\/j.drugalcdep.2026.113243_bib29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.neubiorev.2005.04.016","article-title":"The mesolimbic dopamine system: The final common pathway for the reinforcing effects of drugs of abuse?","volume":"30","author":"Pierce","year":"2006","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"4","key":"10.1016\/j.drugalcdep.2026.113243_bib30","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/sj.bjp.0706757","article-title":"Mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis","volume":"148","author":"Rios","year":"2006","journal-title":"Br. J. Pharmacol."},{"issue":"1-3","key":"10.1016\/j.drugalcdep.2026.113243_bib31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejphar.2010.02.005","article-title":"Effects of cannabinoid receptor antagonists on maintenance and reinstatement of methamphetamine self-administration in rhesus monkeys","volume":"633","author":"Schindler","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2026.113243_bib32","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/npp.2016.27","article-title":"Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys","volume":"41","author":"Schindler","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"1-2","key":"10.1016\/j.drugalcdep.2026.113243_bib33","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0006-8993(02)03842-8","article-title":"Long-term interactions between opioid and cannabinoid agonists at the cellular level: cross-desensitization and downregulation","volume":"960","author":"Shapira","year":"2003","journal-title":"Brain Res."},{"issue":"4","key":"10.1016\/j.drugalcdep.2026.113243_bib34","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/sj.npp.1301476","article-title":"The Novel Cannabinoid CB1 Receptor Neutral Antagonist AM4113 Suppresses Food intake and Food-Reinforced Behavior but Does not Induce Signs of Nausea in Rats","volume":"33","author":"Sink","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.drugalcdep.2026.113243_bib35","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.pbb.2008.07.013","article-title":"Oral bioavailability of the novel cannabinoid CB1 antagonist AM6527: Effects on food-reinforced behavior and comparisons with AM4113","volume":"91","author":"Sink","year":"2009","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"20","key":"10.1016\/j.drugalcdep.2026.113243_bib36","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.3390\/cells11203262","article-title":"Neutral CB1 Receptor Antagonists as Pharmacotherapies for Substance Use Disorders: Rationale, Evidence, and Challenge","volume":"11","author":"Soler-Cede\u00f1o","year":"2022","journal-title":"S. Cells"},{"issue":"11","key":"10.1016\/j.drugalcdep.2026.113243_bib37","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1038\/s41386-024-01861-y","article-title":"AM6527, a neutral CB1 receptor antagonist, suppresses opioid taking and seeking, as well as cocaine seeking in rodents without aversive effects","volume":"49","author":"Soler-Cede\u00f1o","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drugalcdep.2026.113243_bib38","first-page":"491","article-title":"Drug Overdose Deaths in the United States, 2002-2022. National Center for Health Statistics, Center for Disease","author":"Spencer","year":"2024","journal-title":"Control"},{"issue":"12","key":"10.1016\/j.drugalcdep.2026.113243_bib39","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.amjcard.2007.10.011","article-title":"Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential","volume":"100","author":"Steinberg","year":"2007","journal-title":"Am. J. Cardiol."},{"issue":"1","key":"10.1016\/j.drugalcdep.2026.113243_bib40","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: A systematic review","volume":"25","author":"Timko","year":"2016","journal-title":"J. Addict. Dis."},{"issue":"10","key":"10.1016\/j.drugalcdep.2026.113243_bib41","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a012096","article-title":"The neurobiology of opiate motivation","volume":"2","author":"Ting-A-Kee","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"1","key":"10.1016\/j.drugalcdep.2026.113243_bib42","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/npp.2017.126","article-title":"Endocannabinoid Regulation of Reward and Reinforcement through Interaction with Dopamine and Endogenous Opioid Signaling","volume":"43","author":"Wenzel","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drugalcdep.2026.113243_bib43","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1007\/s00213-014-3575-5","article-title":"CB1 antagonism: interference with affective properties of acute naloxone-precipitated morphine withdrawal in rats","volume":"231","author":"Willis","year":"2014","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1016\/j.drugalcdep.2026.113243_bib44","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/alcalc\/37.5.485","article-title":"GABAergic mechanisms of opiate reinforcement","volume":"37","author":"Xi","year":"2002","journal-title":"Alcohol Alcohol"},{"issue":"14","key":"10.1016\/j.drugalcdep.2026.113243_bib45","doi-asserted-by":"crossref","first-page":"12399","DOI":"10.1021\/acs.jmedchem.4c01153","article-title":"Addressing the Opioids Lipophilicity Challenge via a Straightforward and Simultaneous 1H NMR-Based logP\/D Determination, Both Separately and in Mixtures","volume":"67","author":"Yeffet","year":"2024","journal-title":"J. Med. Chem."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871626002243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871626002243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:26:51Z","timestamp":1788528411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871626002243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":45,"alternative-id":["S0376871626002243"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2026.113243","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabinoid (CB) 1 receptor antagonists block fentanyl conditioned place preference but not fentanyl antinociception","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2026.113243","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113243"}}